Agenda

Wednesday, February 3, 2010

3:00–8:00 p.m.

Registration

Thursday, February 4, 2010

7:30–8:00 a.m.

Registration/Continental Breakfast

Session I: Basic Biology and Preclinical Data

Moderator: Lee M. Ellis, MD

8:00–8:30

Opening Remarks/Overview
Lee M. Ellis, MD

8:30–8:55

Breaking VEGF to Pieces: Can the Tail of VEGF be the Beginning of a New Therapy?
Luisa Iruela-Arispe, PhD

8:55–9:20

Reduction of Tumor Invasiveness and Metastasis and Prolongation of Survival After Inhibition of VEGFR plus c-Met in Preclinical Models
Donald McDonald, MD, PhD

9:20–9:35

Identification and Characterization of a Novel Anti-Angiogenic & Anti-Tumorigenic Peptide Derived From Tissue Inhibitor of Metalloproteinases-3*
Yung-Yi Chen, PhD

9:35–10:00

PI3 Kinase Gamma Control of Tumor Inflammation, Angiogenesis and Progression
Judith Varner, PhD

10:00–10:20

Break

10:20–10:45

Will Anti-Angiogenic Drugs be More Effective for Metastatic Disease Than as Neoadjuvant or Adjuvant Therapies?
Robert S. Kerbel, PhD

10:45–11:10

Notch Ligands as Therapeutic Targets in Tumor Angiogenesis
Jan Kitajewski, PhD

11:10–11:35

Targeting the PHD/HIF/VHL Pathway Therapeutically
Amato J. Giaccia, PhD

11:35–12:00 p.m.

Tumor Stroma and Targeted Delivery via Endothelial Caveolae
Jan E. Schnitzer, MD

12:00–1:00

Lunch

Session II: Biomarkers/Resistance Mechanisms

Moderator: Robert S. Kerbel, PhD

1:00–1:25

Circulating Cytokines and Endothelial Cells
John Heymach, MD, PhD

1:25–1:40

SNPs and Anti-VEGF Therapy
Bryan Schneider, MD

1:40–2:05

TKI Therapy RelatedProteomic Patterns in Serum from Patients with Metastatic Renal Cell Carcinoma*
Kerstin Junker, MD, PhD

2:05–2:30

Pro-invasive Growth of Giloma During VEGF Inhibition
Gabriele Bergers, PhD

2:45–3:10

The Biology and Treatment of Acquired VEGF Pathway Resistance in RCC
Michael B. Atkins, MD

3:10–3:30

Break

3:30–4:00

Panel Discussion: Does Anti-Angiogenic Therapy Accelerate Tumor Growth & Metastasis in the Clinic?

Chairs:
Lee M. Ellis, MD
Robert S. Kerbel, PhD

Panelists:
Michael B. Atkins, MD
S. Gail Eckhardt, MD
John Heymach, MD, PhD
David A. Reardon, MD
George W. Sledge, Jr., MD

4:00–5:30 p.m.

Welcome/Poster Reception

Friday, February 5, 2010

7:30–8:00 a.m.

Registration/Continental Breakfast

Session III: Controversies in Anti-Angiogenic Therapy

Moderator: George W. Sledge, Jr., MD

8:00–8:05

Introduction
George W. Sledge, Jr., MD

8:05–8:30

Why Do Drugs Fail?
George W. Sledge, Jr., MD

8:30–8:55

Do We Need Another VEGF Targeted TKI?
S. Gail Eckhardt, MD

8:55–9:20

Development of Hypertension is a BioMarker of Clinical Efficacy for VEGF Inhibiting Agents in Metastatic RCC
Brian Rini, MD

9:20–9:35

Updated Activity and Dafety Results of Phase 2 Randomized Discontinuation Trial (RDT) of Tivozanib (AV-951), a Potent and Selective VEGFR1, 2 and 3 Kinase Inhibitor, in Patients Wwith Renal Cell Carcinoma (RCC)*
Pankaj Bhargava, MD

9:35–10:00

Novel Clinical Trial Designs for Anti-Angiogenic Therapy
Lillian L. Siu, MD

10:00–10:25

Pharmacoeconomics of Anti-VEGF Therapy
Neal J. Meropol, MD

10:25–10:45

Break

Session IV: Early Drug Development

Moderators: Helen X. Chen, MD and George W. Sledge, Jr., MD

10:45–11:00

A Phase I Study of Jl-101, a Multikinase Oral VEGFR TKI with Activity Targeting EphB4
Michael S. Gordon, MD

11:00–11:15

A Phase I Study of the Safety and Phamacokinetics of MEGF0444A (MoAB to EGFL7) Administered IV to Patients with Advanced Solid Tumors
Lee S. Rosen, MD

11:15–11:30

Targeting the Delta-like Ligand 4 (DII4) as a Novel Notch Pathway-Mediated Anti-Angiogenic Strategy: A First-in-Human Study
Antonio Jimeno, MD, PhD

11:30–11:45

Phase I Trial With PTC299 in Patients with Advanced Solid Tumors
Gary W. Schwartz, MD

11:45–12:10 p.m.

Combinations With Anti-Angiogenic Therapy
Helen X. Chen, MD

12:10–1:10

Lunch

Session V: Clinical Trial Results

Moderator: Helen X. Chen, MD

1:10–1:35

Anti-Angiogenic Therapy for the Treatment of Breast Cancer
Mark Pegram, MD

1:35–2:00

Anti-Angiogenic Therapy for Hepatocellular Carcinoma
Melanie B. Thomas, MD

2:00–2:15

A Phase II Study of Neoadjuvant Bevacizumab and Radiation Therapy for Resectable Soft Tissue Sarcomas*
Sam Yoon, MD

2:15–2:35

Break

2:35–3:00

Anti-Angiogenic Therapy for NETS
Lillian L. Siu, MD

3:00–3:25

Anti-Angiogenic Therapy for Metastatic Melanoma: First Wave of Results From Randomized Trials With VEGF-Targeted Therapy in Melanoma
Keith T. Flaherty, MD

3:25–3:50

Imaging of Anti-Angiogenic Therapy
Peter Choyke, MD

4:00

Adjourn

Saturday, February 6, 2010

7:30 - 8:00 a.m.

Registration/Continental Breakfast

Session VI: Clinical Trial Results

Moderator: Michael S. Gordon, MD

8:00–8:05

Introduction
Michael S. Gordon, MD

8:05–8:30

Anti-Angiogenic Therapy for the Treatment of Ovarian & Endometrial Cancers
Robert Allen Burger, MD

8:30–8:55

Vascular Disrupting Agents
Roberto Pili, MD

8:55 –9:20

VEGF Targeted Drugs Piling Up in Renal Cell Carcinoma: What Will be the Next Innovation?
Keith T. Flaherty, MD

9:20–9:40

Break

9:40–10:05

Anti-Angiogenic Therapy for the Treatment of CNS Malignancies
David A. Reardon, MD

10:05–10:30

Anti-Angiogenic Therapy for the Treatment of Lung Cancer
John Heymach, MD, PhD

10:30–10:55

Anti-Angiogenic Therapy for the Treatment of Gastric/Esophageal Cancer
Manish Shah, MD

10:55–11:20

Anti-Angiogenic Therapy for the Treatment of CRC
Neal J. Meropol, MD

11:20–11:25

Closing Remarks

11:30

Adjourn